Revenue
2020
2021
2022
2023
2024
2025
Zomedica Corp. (ZOMDF)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.3M | $25.2M | $18.9M | $4.1M | $0 | — | — | — | — |
| Gross profit | $21.7M | $19.1M | $17.3M | $13.5M | $3.1M | $0 | — | — | — | — |
| Research & development | $7.2M | $7.3M | $5.7M | $2.6M | $1.7M | $8.0M | $10.3M | $10.3M | $2.8M | $1.5M |
| Operating income | −$84.4M | −$51.1M | −$43.3M | −$21.9M | −$21.4M | −$16.8M | −$19.8M | −$16.6M | −$8.1M | −$5.7M |
| EBITDAderived | −$76.4M | −$43.1M | −$37.0M | −$17.9M | −$20.2M | −$16.5M | −$19.5M | −$16.4M | −$8.0M | −$5.7M |
| Net income | −$81.9M | −$47.0M | −$34.5M | −$17.0M | −$18.4M | −$16.9M | −$19.8M | −$16.6M | −$8.1M | −$5.7M |
| Basic EPSper diluted share | -$0.08 | -$0.05 | -$0.04 | -$0.02 | -$0.05 | -$0.05 | -$0.19 | -$0.18 | -$0.09 | -$0.07 |
| Diluted EPSper diluted share | -$0.08 | -$0.05 | -$0.04 | -$0.02 | -$0.05 | -$0.05 | -$0.19 | -$0.18 | -$0.09 | -$0.07 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2026Form 4 | Klass Russell KevinSr. Vice President, Sales | BuyCommon Stock, without par value · indirect | 104.0K | $0.10 | $10.4K | 104.0K |
| May 21, 2026Form 4 | Klass Russell KevinOther | BuyCommon Stock, without par value | 5.5K | $0.11 | $605.00 | 6.00M |
| May 21, 2026Form 4 | Klass Russell KevinOther | BuyCommon Stock, without par value | 11.4K | $0.11 | $1.3K | 6.00M |
| May 20, 2026Form 4 | POWERS JOHNNY DDirector | BuyCommon Stock, without par value | 97.5K | $0.10 | $9.8K | 4.42M |
| May 20, 2026Form 4 | Klass Russell KevinOther | BuyCommon Stock, without par value | 200.0K | $0.11 | $22.0K | 5.98M |